Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroinflammation: a potential therapeutic target.

Jeffrey M Craft1, D Martin Watterson, Linda J Van Eldik

  • 1Center for Drug Discovery and Chemical Biology, Northwestern University, Feinberg School of Medicine, 303 E. Chicago Avenue, Mail Code W-896, Chicago, IL 60611-3008,USA.

Expert Opinion on Therapeutic Targets
|September 28, 2005
PubMed
Summary

Developing novel therapeutics targeting neuroinflammation shows promise for neurodegenerative diseases. New drug classes targeting specific glial activation pathways offer better efficacy and safety than repurposed drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermittent Hypoxemia in Preterm Infants: Glial Fibrillary Acidic Protein as a Potential Brain Injury Biomarker.

Respiratory physiology & neurobiology·2026
Same author

Glial cytokine modulation improves sleep and circadian disruption in female SAA knock-in mice of Alzheimer's-related pathology.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

A Novel Anti-Inflammatory Small Molecule MW189 Reduces Microglial Activation and Improves Functional Outcomes in a Murine Model of Subarachnoid Hemorrhage.

Neurocritical care·2026
Same author

Intermittent Hypoxemia and Brain Injury Biomarker S100B in Preterm Infants.

Neonatology·2026
Same author

Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIA.

Nature communications·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Neuroinflammation, driven by glial cells, is increasingly recognized in neurodegenerative disease progression.
  • Existing drugs repurposed for neuroinflammation often show limited efficacy or adverse effects.
  • Targeting neuroinflammation is crucial for developing effective treatments for neurological disorders.

Purpose of the Study:

  • To review current clinical and preclinical strategies for targeting neuroinflammation in neurodegenerative diseases.
  • To evaluate the success of repurposed drugs versus novel therapeutics.
  • To discuss the potential of targeting specific glial pathways for new treatments.

Main Methods:

  • Review of clinical and preclinical data on neuroinflammation therapeutics.

Related Experiment Videos

  • Analysis of approaches targeting glial activation pathways.
  • Examination of preclinical animal models for Alzheimer's disease and other neurodegenerative disorders.

    • Main Results:

    • Repurposed drugs have largely failed to effectively treat neuroinflammation.
    • Novel therapeutic development targeting selective glial pathways shows promising preclinical results.
    • Targeting glia-specific pathways offers a more effective strategy than targeting general inflammatory responses.

    Conclusions:

    • De novo development of therapeutics targeting glial pathways is a promising avenue for neurodegenerative diseases.
    • Targeting neuroinflammation selectively in the central nervous system is key.
    • Findings from Alzheimer's disease models are applicable to other neuroinflammatory disorders.